Shares of Corium International Inc. (NASDAQ:CORI) have received an average recommendation of “Buy” from the six brokerages that are covering the firm. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $13.80.

CORI has been the subject of several research analyst reports. FBR & Co set a $18.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Corium International in a research note on Monday, September 26th. Leerink Swann set a $16.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Tuesday. Finally, Jefferies Group set a $9.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Thursday.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RTW Investments LLC increased its position in Corium International by 22.6% in the third quarter. RTW Investments LLC now owns 1,045,747 shares of the biopharmaceutical company’s stock valued at $5,888,000 after buying an additional 192,786 shares during the period. Paloma Partners Management Co purchased a new position in shares of Corium International during the second quarter valued at approximately $152,000. Finally, Opaleye Management Inc. increased its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the last quarter. 88.35% of the stock is owned by institutional investors.

Corium International (NASDAQ:CORI) opened at 5.51 on Monday. The stock’s 50 day moving average is $5.02 and its 200 day moving average is $4.72. Corium International has a one year low of $3.14 and a one year high of $9.93. The firm’s market capitalization is $122.36 million.

WARNING: “Corium International Inc. (CORI) Receives $13.40 Consensus Target Price from Brokerages” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/26/corium-international-inc-cori-receives-13-40-consensus-target-price-from-brokerages.html.

About Corium International

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.